Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

SEC: Men Made ‘Illicit Profits’ in Sanofi-Chattem Deal
WSJ Online
Monday, December 28, 2009 - 4:43am
tags:
Sanofi, Chattem, M&A, SEC
MedImmune responds to FDA on pediatric drug
Bizjournals.com
Monday, December 28, 2009 - 4:41am
tags:
FDA, MedImmune, Synagis, RSV
The 5 Worst Drug Companies of 2009
BNET Pharma
Monday, December 28, 2009 - 4:40am
tags:
Mylan, Elan, Genzyme, Sequenom, Ranbaxy
Sanofi Said to Drop Bid for German Generics Maker Ratiopharm
Bloomberg
Monday, December 28, 2009 - 4:39am
tags:
generics, Sanofi, Ratiopharm, M&A
CompuGen-Pfizer Deal: What Biotech 'Dreamers' Can Accomplish
Seeking Alpha
Monday, December 28, 2009 - 4:38am
tags:
Pfizer, CompuGen, partnerships
Lilly Prepares for Patent Loss in Psychosis Drug, Moves into Arthritis Market
Seeking Alpha
Monday, December 28, 2009 - 4:36am
tags:
Eli Lilly, arthritis, patents, generics, Incyte, Zyprexa
Pfizer's Lyrica for GAD Rejected by FDA
TheStreet.com
Monday, December 28, 2009 - 4:35am
tags:
GAD, generalized anxiety disorder, Pfizer, FDA, Lyrica
Bristol-Myers lowers 2009 outlook after Mead deal
Yahoo/Reuters
Wednesday, December 23, 2009 - 9:54am
tags:
Mead Johnson, outlook, Bristol-Myers Squibb
Cephalon hikes Provigil price to push new med
Fierce Pharma
Wednesday, December 23, 2009 - 8:54am
tags:
Cephalon, drug pricing, Provigil, jet lag
Exelixis, Inc.: Warming Up or Cooling Off?
Motley Fool
Wednesday, December 23, 2009 - 8:51am
tags:
Exelixis
2009 Biotech Cheers and Jeers
Motley Fool
Wednesday, December 23, 2009 - 8:43am
tags:
Human Genome Sciences, GSK, Vanda, Sequenom, Genzyme, Amgen, Merck, Eli Lilly
Partnering Activity Skyrockets as Biotechs Close Year-End Deals
BNET Pharma
Wednesday, December 23, 2009 - 8:38am
tags:
biotech, * Incyte, Eli Lilly, OncoGenex, Teva Pharmaceuticals, Biovitrum, Eisai, AkaRx, Thallion Pharmaceuticals, LFB Biotechnologies, Athersys, Pfizer, Myriad, Javelin, Durata Therapeutics, Vicuron
Bristol-Myers Squibb and Mead Johnson Announce Final Results of the Exchange Offer
Yahoo
Wednesday, December 23, 2009 - 8:37am
tags:
M&A, Bristol-Myers Squibb, Mead Johnson
It’s Official: Roche Infringed On Amgen Patents
Pharmalot
Wednesday, December 23, 2009 - 8:27am
tags:
Amgen, Roche, patents, anemia, Mircera
Medicines Co. licenses potential anti-plaque drug from Pfizer in deal that could top $420M
Yahoo/AP
Wednesday, December 23, 2009 - 8:25am
tags:
Pfizer, Medicines Company, liscensing, ApoA-I Milano
AstraZeneca’s Swine Flu Nasal Spray Recalled for Lower Potency
Bloomberg
Wednesday, December 23, 2009 - 8:23am
tags:
AstraZeneca, swine flu, vaccines, recalls, H1N1
Pfizer Jury Said to Set Prempro Punitive Damages at $8 Million
Bloomberg
Wednesday, December 23, 2009 - 8:22am
tags:
Prempro, lawsuits, Pfizer, Wyeth
Novartis Buying U.S. Maker of Heart Drug
TheStreet.com
Wednesday, December 23, 2009 - 8:17am
tags:
Novartis, M&A, Corthera, Relaxin
Look for Novartis-Alcon Deal in Early 2010
WSJ Online
Tuesday, December 22, 2009 - 4:12pm
tags:
Novartis, Alcon, M&A
FDA to issue decision on Shire's Gaucher drug
Marketwatch
Tuesday, December 22, 2009 - 4:11pm
tags:
FDA, Shire, Gaucher disease

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.